Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins. The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease. Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases. The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.
